
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **June 29, 2017**

BioTime, Inc.

(Exact name of registrant as specified in its charter)

California
(State or other jurisdiction
of incorporation)

1-12830
(Commission
File Number)

94-3127919
(IRS Employer
Identification No.)

**1010 Atlantic Avenue
Suite 102
Alameda, California 94501**
(Address of principal executive offices)

(510) 521-3390
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's other reports filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions identify forward-looking statements.

References in this Report to "BioTime," "we" or "us" refer to BioTime, Inc.

This Report and the accompanying Exhibit 99.1 shall be deemed "furnished" and not "filed" under Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any filings made by BioTime under the Securities Act of 1933, as amended, or the Exchange Act except as may be expressly set forth by specific reference in such filing.

Section 7 - Regulation FD

Item 7.01 - Regulation FD Disclosure

On June 29, 2017, BioTime may present some or all of the information in the slides attached as Exhibit 99.1 at its 2017 Annual Meeting of Shareholders.

Section 9 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
-----------------------	--------------------

99.1	Slide presentation
------	--------------------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOTIME, INC.

Date: June 29, 2017

By: /s/ Adi Mohanty

Co-Chief Executive Officer



Leading the Regenerative Medicine Revolution

NYSE MKT: BTX

Update on BioTime's Subsidiary AgeX Therapeutics


Annual Meeting of
Shareholders

June 29, 2017

Safe Harbor Statement


The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of BioTime in developing new stem cell products and technologies; results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain additional FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime products; and the ability of BioTime to raise the capital needed to finance its current and planned operations. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. As actual results may differ materially from the results anticipated in these forward-looking statements they should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

Telomeres as a Clocking Mechanism




Pluripotency

- Scalable source of all human cell types
- Immortal cells allow sophisticated genetic modifications
- Regen phenotype




2nd Generation - Universal PureStem™ Technology

Traditional Manufacture



PureStem™ Technology



>200-fold diversity
Scalable, monoclonally-
purified regenerative
progenitors



Planned Product Focus

- AgeX consolidates certain early-stage assets and research outside of BioTime's current three core areas of ophthalmology, aesthetics, and delivery.
- Our objective in forming AgeX is to find a way to unlock the potential value of these non-core assets for our existing shareholders, while at the same time, further simplifying the BioTime structure
- AgeX has three new programs slated for development
 - Type II diabetes
 - Age-related ischemic disease
 - Scarless tissue regeneration; all based in part on an exciting new understanding of how and why we age.


Brown Adipose Cells Regulate Metabolism



Brown Adipose Cells Regulate Metabolism



Brown Adipose Tissue Activity (PET-CT with ^{18}F -FDG)



Obesity (2011) **19**, 1755–1760. doi:10.1038/oby.2011.125

New Powers of Brown Fat: Fighting the Metabolic Syndrome

Jan Nedergaard,^{1,*} Tore Bengtsson,¹ and Barbara Cannon¹

¹The Wenner-Gren Institute, Stockholm University, Stockholm 106 91, Sweden

*Correspondence: jan@metabol.su.se

DOI 10.1016/j.cmet.2011.02.009

ORIGINAL ARTICLE

Reversal of Type 1 Diabetes in Mice by Brown Adipose Tissue Transplant

Subhadra C. Gunawardana and David W. Piston


Brown adipose tissue regulates glucose homeostasis and insulin sensitivity

Kristin I. Stanford, Roeland J.W. Middelbeek, Kristy L. Townsend, Ding An,
Eva B. Nygaard, Kristen M. Hitchcox, Kathleen R. Markan, Kazuhiro Nakano,
Michael F. Hirshman, Yu-Hua Tseng, and Laurie J. Goodyear


Section on Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA

Industrially-Scalable AgeX-BAT1

Stained for Brown Adipocyte Marker UCP1



Tissue-Sourced Brown Adipocytes



PureStem Brown Adipocytes

Obesity/T2D Market/Competition


- 30M Americans have diabetes¹ 1:3 Americans will have diabetes by 2050
- The global market for diabetes mellitus and obesity is set to rise from \$70.8 billion in 2015 to \$163.2 billion by 2022, at a strong compound annual growth rate of 12.7%, according to business intelligence firm GBI Research².
- Invokana, which is marketed by Johnson & Johnson, is one of the key players in the disease cluster. It is expected to reach a huge \$3.23 billion by 2022, and is set to be approved across T1DM, T2DM and obesity.
- Invokana belongs to a newer class of Type 2 diabetes treatments called sodium-glucose co-transporter 2 (SGLT2) inhibitors, a class of medication that works by stopping glucose from being reabsorbed into the blood. The FDA warned Invokana can also cause ketoacidosis, a condition that requires hospitalization and can cause fatal swelling of the brain, severe dehydration and coma.

1) Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. US Department of Health and Human Services; Atlanta, GA: 2014.


2) <http://www.gbiresearch.com/media-center/press-releases/diabetes-and-obesity-therapeutics-market-will-more-than-double-to-1632-billion-by-2022-says-gbi-research>

Regenerative Vascular Progenitors

Monoclonal Endothelial Cells



100% Purity



- Highly scalable with high purity & potency
- Extensive IP estate
- Formulated in a proprietary matrix with good safety profile for human lipotransfer

Cardiovascular Market

> \$Trillion Market Worldwide¹




	Current	2035
Medical costs up 135 percent	\$318 billion	\$749 billion
Indirect costs up 55 percent (Lost productivity)	\$237 billion	\$368 billion
TOTAL COSTS	\$555 billion	\$1.1 trillion

The Cost Generators: Aging Baby Boomers

As Baby Boomers age, costs for CVD will shift from middle-aged Americans to individuals ages 65 and over. By 2035, Boomers who are 80 and older will be the source of the largest cost increases for CVD.


1) http://www.heart.org/idc/groups/heart-public/@wcm/@adv/documents/downloadable/ucm_491543.pdf

Induced Tissue Regeneration (iTR)




Telomerase & iTR

Animals that have telomerase expression and full regenerative potential do not age




Int. J. Mol. Sci. 2015, 16, 25392-25432

An Example of an iTR Gene During Aging



Aging: The demographic trend of our time



U.S. Bureau of the Census

- 80% of \$2.5T health care costs associated with chronic disease.
- Four chronic diseases: heart, cancer, stroke, and diabetes cause 2/3 deaths in U.S.

Aging: The demographic trend of our time

The Obsession With 'Curing' Aging Is Now Big Business

by Laura Lorenzetti

@lauralorenzetti

MARCH 7, 2016, 6:00 AM EDT



Fortune.com



- Powerful technology to address aging: The demographic trend of our time
- Goal: to unlock shareholder value for BTX non-core assets
- Three therapeutic programs with potential to address large causes of mortality in U.S.
 - T2D/Obesity: One of the largest and fastest growing markets with *AGEX-BAT1* being highly novel
 - Cardiac/Cerebral Ischemia: The leading causes of mortality & disability in an aging population
 - iTR: Targeting degenerative disease using new paradigm
 - Strong intellectual property

